title: Outcome of Rhabdomyosarcoma in First Year of Life: Children's Cancer Hospital 57357 Egypt.
abstract: Background. Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in children. Fifty percent of RMS cases occur in the first 10 years of life and less commonly in infants younger than one-year old. These infants require adapted multimodality treatment approaches. Patients and Methods. We analyzed patients' characteristics, treatment modalities, and the outcome for RMS infants treated at Children's Cancer Hospital Egypt (CCHE) between July 2007 and December 2010 and compared them to patients above one year treated on the same protocol. Results. Out of the 126 RMS treated during this period, 18 were below the age of one year. The male: female ratio was 1.25 : 1. The median age at diagnosis was 0.7 ± 0.2 years. Most of the cases (27.8%) were presented in head and neck regions. The estimated 4-years failure-free survival and overall survival for infants were 49 ± 12% and 70 ± 12%, respectively. These failure-free survival rate and overall survival rate did not differ from those for older patients (P = 0.2). Conclusion. Infants with RMS are a unique group of RMS who needs special concerns in tailoring treatment in addition to concerns regarding toxicity and morbidity in infants.
authors: Department of Pediatric Hematology/Oncology, Children's Cancer Hospital Egypt 57357 (CCHE), 1 Seket El-Emam, Sayeda Zeinab, Cairo 11441, Egypt.
authors: Enas
authors: E
authors: El Nadi
authors: Emad A H
authors: EA
authors: Moussa
authors: Wael
authors: W
authors: Zekri
authors: Hala
authors: H
authors: Taha
authors: Alaa
authors: A
authors: Yones
authors: Mohamed Saad
authors: MS
authors: Zaghloul
authors: Madeeha
authors: M
authors: El Wakeel
authors: Rania M
authors: RM
authors: Labib
references: Cancer. 1986 Dec 15;58(12):2606-10
references: 3779610
references: J Clin Oncol. 2009 Nov 1;27(31):5182-8
references: 19770373
references: Pediatr Blood Cancer. 2004 Jan;42(1):64-73
references: 14752797
references: Cancer. 2011 Aug 1;117(15):3493-501
references: 21264837
references: Cancer. 1995 Sep 15;76(6):1073-85
references: 8625211
references: Curr Top Dev Biol. 2011;94:197-234
references: 21295688
references: J Clin Oncol. 2006 Aug 20;24(24):3844-51
references: 16921036
references: Cancer. 2003 May 15;97(10):2597-604
references: 12733159
references: Arch Pathol Lab Med. 2006 Oct;130(10):1454-65
references: 17090187
references: Cancer. 1987 Oct 1;60(7):1552-60
references: 3621128
references: Med Pediatr Oncol. 1989;17(2):105-10
references: 2704331
references: J Clin Oncol. 2005 Jul 1;23(19):4363-71
references: 15994146
references: Am J Pediatr Hematol Oncol. 1981 Fall;3(3):287-96
references: 7025684
references: J Pediatr Surg. 1994 Aug;29(8):1167-70
references: 7965528
references: Cancer. 1988 Jan 15;61(2):209-20
references: 3275486
references: Cancer. 2001 Sep 15;92(6):1613-20
references: 11745240
references: Med Pediatr Oncol. 1989;17(5):424-8
references: 2796858
references: J Dent Res. 2012 Apr;91(4):341-50
references: 21917598